TRA-8 is a murine agonist monoclonal antibody to death receptor 5 (DR5), which is able to trigger apoptosis in DR5 positive human tumor cells without the aid of crosslinking. It has demonstrated cytotoxicity in vitro and in vivo antitumor efficacy to a wide range of solid tumors in murine xenograft models. Tigatuzumab is a humanized IgG1 monoclonal antibody derived from TRA-8.
Methods:
A phase I trial of tigatuzumab in patients with relapsed/refractory carcinomas (n = 16) or lymphoma (n = 1) was designed to determine the maximal tolerated dose (MTD), pharmacokinetics, immunogenicity, and safety. Three to six (3–6) patients were enrolled in successive escalating cohorts at doses ranging from 1 to 8 mg/kg weekly.
Results:
Seventeen (17) patients enrolled, 9 in the 1-, 2-, and 4-mg/kg dose cohorts (3 in each cohort) and 8 in the 8-mg/kg dose cohort. Tigatuzumab was well tolerated with no DLTs observed, and the MTD was not reached. There were no study-drug–related grade 3 or 4, renal, hepatic, or hematologic toxicities. Plasma half-life was 6–10 days, and no anti-tigatuzumab responses were detected. Seven (7) patients had stable disease, with the duration of response ranging from 81 to 798 days.
Conclusions:
Tigatuzumab is well tolerated, and the MTD was not reached. The high number of patients with stable disease suggests antitumor activity.
Get full access to this article
View all access options for this article.
References
1.
WileySR, SchooleyK, SmolakPJet al.Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995; 3:673.
2.
DanielPT, KrammerPH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol, 1994; 152:5624.
de VriesEG, GietemaJA, de JongS. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res, 2006; 12:2390.
5.
Carlo-StellaC, LavazzaC, LocatelliAet al.Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res, 2007; 13:2313.
6.
AshkenaziA, PaiRC, FongSet al.Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 1999; 104:155.
7.
DebatinKM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother, 2004; 53:153.
8.
ChaudharyPM, EbyM, JasminAet al.Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity, 1997; 7:821.
9.
TolcherAW, MitaM, MeropolNJet al.Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol, 2007; 25:1390.
10.
RowinskyEK. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol, 2005; 23:9394.
11.
IchikawaK, LiuW, ZhaoLet al.Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med, 2001; 7:954.
12.
BuchsbaumDJ, ZhouT, GrizzleWEet al.Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res, 2003; 9:3731.
13.
DeRosierLC, BuchsbaumDJ, OliverPGet al.Combination treatment with TRA-8 antideath receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res, 2007; 13:5535s.
14.
TherasseP, ArbuckSG, EisenhauerEAet al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000; 92:205.
15.
ListerTA, CrowtherD, SutcliffeSBet al.Report of a committee convened to discuss the evaluations and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 1989; 7:1630.
16.
ChesonBD, HorningSJ, CoiffierBet al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 1999; 17:1244.
17.
OliverPG, LoBuglioAF, ZinnKRet al.Treatment of human cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res, 2008; 14:2180.
18.
DerosierLC, VickersSM, ZinnKRet al.TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther, 2007; 6:3198.
19.
LongJW, DerosierLC, VickersSMet al.TRA-8 (TRAIL-R2 antibody)-based combination chemotherapy produces a survival benefit in a pancreatic cancer orthotopic model. J Surg Res, 2007; 137:167.
20.
EstesJM, OliverPG, StraughnJMJr.et al.Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol, 2007; 105:291.
21.
KendrickJE, StraughnJMJr., OliverPGet al.Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol, 2008; 108:591.
22.
KaliberovS, StackhouseMA, KaliberovaLet al.Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene Ther, 2004; 11:658.
23.
FiveashJB, GillespieGY, OliverPGet al.Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys, 2008; 71:507.
24.
PlummerR, AttardD, PaceySet al.Phase 1 and pharmacokinetic study of Lexatumumab in patients with advanced cancers. Clin Cancer Res, 2007; 13:6187.
25.
AdamsC, TotpalK, LawrenceDet al.Structural and functional analysis of the interaction between the agonistic monoclonal antibody, Apomab, and the proapoptotic receptor, DR5. Cell Death Differ, 2008; 15:751.
26.
LiJ, TangB, ChengJet al.Antitumor efficacy of LBY135, an anti-DR5 monoclonal antibody, alone or in combination with chemotherapy in human colon tumor cell lines and xenografts. AACR Meeting Abstracts, 2007Abstract 4874.
27.
WangJ, LinZ, QiaoCXet al.Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis. Cell Mol Immunol, 2008; 5:55.
28.
WallJ, CollotonM, HuardJet al.AMG 655, a monoclonal antibody agonist directed against death receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherapeutic agents. AACR Meeting Abstracts, 2008Abstract 1326.
29.
Kaplan-LefkoP, BushT, BelmontesBet al.AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. AACR Meeting Abstracts, 2008Abstract 399.
